Latest news and press releases about Azitra, Inc. (AZTR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Azitra, Inc. is a pre-clinical biopharmaceutical company focused on developing precise treatments for various dermatological conditions. They innovate by utilizing engineered proteins and live biotherapeutic products to address skin diseases. The company's pipeline features several key therapeutic candidates: ATR-12: A genetically modified strain of S. epidermidis intended to treat Netherton syndrome, a specific skin disorder. ATR-04: Another modified S.
Price
| Price | $0.16 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Valuation Ratios
| Price / Book | 0.41 |
| EV / EBITDA | 0.84 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -205.45% |
| Return on Invested Capital | -159.45% |
| Return on Assets | -137.65% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ENVB · INDP · JSPR · LIPO · ONCO · REVB · SCNI
Explore sector: Healthcare · Biotechnology
More sections of AZTR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks